Neo-adjuvant Followed by Adjuvant Pembrolizumab for Stage III Macroscopic Resectable Melanoma (≥ 12 Years) [2426]

Objectives

Establish routine NHS England commissioning of neoadjuvant followed by adjuvant pembrolizumab for eligible people aged 12 years and over with macroscopic, resectable stage III melanoma, shifting initiation of systemic treatment from after surgery to before surgery. The intended clinical purpose is to reduce progression from stage III to stage IV melanoma, for which five-year survival is substantially lower.[1][2]

• Provide a 54-week treatment pathway comprising pembrolizumab before surgery and continued pembrolizumab as adjuvant therapy after resection.[3][4]
• Cover histologically confirmed cutaneous, acral or mucosal melanoma at stage IIIB, IIIC or IIID where disease is macroscopic and surgically resectable.[3][2][5]
• Limit access to people aged 12 years and over because the policy identifies insufficient evidence to establish safety in younger children.[1]
• Support use of pembrolizumab in a neoadjuvant sequence despite this being off-label, as its licence covers adjuvant use in advanced melanoma and completely resected stage IIB, IIC or III disease.[3]
• Align the policy with existing National Institute for Health and Care Excellence guidance on pembrolizumab for melanoma.[1]

The clinical rationale is that neoadjuvant therapy can generate greater anti-tumour T-cell responses and has improved clinical outcomes for pembrolizumab and the broader class of immune checkpoint inhibitors. NHS England considered the available evidence sufficient for routine commissioning.[1][3]

Implementation

Deliver pembrolizumab through a specialist, multidisciplinary cancer pathway that assesses resectability, administers treatment before and after surgery, and applies defined clinical eligibility, safety, governance and prior-approval requirements. The overall course retains the same total number of pembrolizumab cycles, scans and appointments as the previous treatment pathway.[3][6]

• Assess visible or palpable stage III melanoma and associated lymph-node disease through a multidisciplinary team to determine whether complete tumour resection and therapeutic lymph-node dissection are feasible, then refer suitable patients to oncology for systemic treatment consideration.[3][5]
• Require surgery after neoadjuvant treatment, with the supplied policy material describing surgery within three weeks of the final dose and, elsewhere, within three to five weeks; begin adjuvant treatment as soon as safely possible after surgery and within three months.[5][4]
• Administer three neoadjuvant pembrolizumab cycles before surgery, then continue adjuvant treatment to complete 54 weeks unless distant disease progression, unacceptable toxicity or withdrawal of consent occurs.[5][4]
• Restrict treatment to patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and no previous treatment with programmed death 1, programmed death ligand 1, programmed death ligand 2 or cytotoxic T-lymphocyte-associated antigen 4 antibodies.[5]
• Exclude uveal melanoma, microscopic disease, prior melanoma immunotherapy, cases in which surgery was not planned at initial diagnosis or first detected nodal disease, and patients with product-specific contraindications.[5]
• Initiate and manage treatment through an oncologist accredited and experienced in systemic anti-cancer therapy, melanoma and immunotherapy.[5]
• Undertake baseline full blood count, urea and electrolytes, liver and thyroid function tests, blood glucose measurement and electrocardiogram assessment before treatment.[5]
• Review tolerability formally by the start of the third three-weekly neoadjuvant cycle and follow additional monitoring requirements in the Summary of Product Characteristics.[4]

For adults, pembrolizumab may be administered intravenously every three or six weeks, with specified subcutaneous options where clinically indicated. Subcutaneous pembrolizumab is not commissioned for patients under 18 years of age.[4]

Care must be delivered in specialised centres, or collaboratively with specialised centres, under multidisciplinary team supervision. The policy operates alongside service specifications for adult chemotherapy and specialist cancer services for teenagers, young adults and children.[6]

• Complete provider internal governance approval before prescribing, potentially through a Trust Drugs and Therapeutics Committee or an equivalent body.[6]
• Register patients using prior-approval software and maintain evidence that treatment criteria are met.[6]
• Use prior-approval registration and compliance data for audit and to inform future policy revision.[6]
• Review the policy when new information warrants revision, including when new evidence results in a Preliminary Policy Proposal.[6]
• Commission and fund treatment initiation and maintenance through existing specialised-services arrangements, subject to therapy prices and commercial terms remaining at or below those evaluated.[6]

No formal performance indicators, reporting timetable or wider accountability framework are specified beyond clinical monitoring, prior approval, compliance data, audit and policy review. Approximately 440 patients are estimated to be eligible, including people switching from previous treatment pathways; no budget, treatment price or funding-gap estimate is specified.[2][6]

Monitoring & Evaluation

Monitoring and accountability combine clinical oversight, treatment-specific safety review, prior approval registration and compliance data. No formal outcome indicator set, reporting schedule, surveillance system or fixed evaluation timetable is specified in the supplied material.[1][5][6]

• Conduct multidisciplinary team assessment to confirm that macroscopic stage IIIB to IIID melanoma and associated nodal disease are resectable before referral for systemic treatment consideration.[3]
• Require treatment initiation and management by an oncologist accredited and experienced in systemic anti-cancer therapy, melanoma and immunotherapy.[5]
• Undertake baseline full blood count, urea and electrolyte, liver-function, thyroid-function and blood-glucose testing, together with an electrocardiogram, before treatment.[5]
• Review treatment tolerability formally by the start of the third three-weekly neoadjuvant pembrolizumab cycle, with further monitoring undertaken in accordance with the medicine’s Summary of Product Characteristics.[4]
• Stop treatment for distant disease progression, unacceptable toxicity or withdrawal of consent, rather than continuing automatically for the full planned course.[5]
• Register patients through prior approval software and retain evidence that treatment criteria have been met.[6]
• Collect prior approval registration and compliance-monitoring data to support audit and inform future policy revisions.[6]
• Review the policy when new information indicates that amendment is needed, including when a new evidence base results in submission of a Preliminary Policy Proposal.[6]

The commissioning decision was supported by NHS England’s conclusion that available evidence was sufficient for routine availability, with committee support for a routine commissioning policy.[1]The clinical rationale cited evidence that neoadjuvant therapy produces greater anti-tumour T-cell activity and improves clinical outcomes for pembrolizumab and other immune checkpoint inhibitors.[3]

Eligibility controls also function as accountability mechanisms: patients must be aged 12 years or over, have eligible histologically confirmed melanoma, have no prior programmed death 1, programmed death ligand 1, programmed death ligand 2 or cytotoxic T-lymphocyte-associated antigen 4 antibody therapy, and have an Eastern Cooperative Oncology Group performance status of 0 or 1.[2][5]Uveal melanoma, microscopic disease, unplanned surgery at initial diagnosis or first detected nodal disease, and product-specific contraindications are excluded.[5]

Costing & Financing

NHS England commissions and funds initiation and maintenance of neoadjuvant followed by adjuvant pembrolizumab for eligible patients through existing specialised-services arrangements.[6]The supplied material gives no treatment price, total budget, programme allocation, funding gap, resource-mobilisation plan or wider economic assumptions.[1][2]

• Fund treatment only where therapy prices and commercial terms are at or below the levels submitted for evaluation.[6]
• Review the policy if the supplier no longer provides treatment on those terms or cannot match price reductions available for alternative therapies.[6]
• Plan for an estimated eligible population of approximately 440 patients, including people moving from prior treatment pathways.[2]
• Maintain the same total number of pembrolizumab cycles, scans and appointments as under the existing treatment pathway, indicating that the policy changes treatment timing rather than adding a stated course of treatment activity.[3]
• Deliver treatment through specialised centres, or collaboratively with specialised centres, under multidisciplinary team supervision; provider organisations must also complete internal prescribing-governance processes.[6]

The treatment pathway comprises 54 weeks of pembrolizumab, including three neoadjuvant cycles before surgery and subsequent adjuvant treatment.[4]Although this establishes the planned treatment duration, the source does not attach a monetary value to the medicine, administration, monitoring, surgery, diagnostics or specialised-centre delivery requirements.[4][1]

Commercial access conditions are explicit, but the material does not quantify the financial consequences of the estimated patient cohort, any savings or additional costs relative to post-surgical initiation, or the costs of prior approval, audit and clinical monitoring.[2][6]